A Phase 3 interventional study of Adalimumab and Methotrexate in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-19.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 38th largest by enrollment, is one of 2 that started in 2014, is one of 26 in phase 3, and was the 30th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 42nd largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2014, is one of 31 in phase 3, and was the 29th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Screening clinical laboratory analyses show any of the following abnormal laboratory results:
The following treatments are prohibited for all subjects during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
Drug: Adalimumab · Drug: Methotrexate
Administered by subcutaneous injection every other week.
Also known as: Humira
Methotrexate was provided as 2.5 mg tablets for oral administration.
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment
Study investigators were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
Time frame: Week 16
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment
Participants were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
Time frame: Week 16
Percentage of Participants Achieving a Satisfactory Response Based on Investigator Assessment Over Time
Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
Time frame: Baseline, week 8 and week 24
Percentage of Participants Achieving a Satisfactory Response Based on Patient Self-assessment Over Time
Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
Time frame: Baseline, week 8 and week 24
Number of Participants Achieving Each Satisfactory Category Based on Investigator Assessment Over Time
Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied
Time frame: Baseline, weeks 8, 16, and 24
Number of Participants Achieving Each Satisfactory Category Based on Patient Self-assessment Over Time
Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied
Time frame: Baseline, weeks 8, 16, and 24
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 50 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is defined as at least a 50% reduction (improvement) from baseline in PASI score.
Time frame: Baseline and Weeks 8, 16, and 24
Percentage of Participants Who Achieved a PASI 75 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from baseline in PASI score.
Time frame: Baseline and Weeks 8, 16, and 24
Percentage of Participants Who Achieved a PASI 90 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is defined as at least a 90% reduction (improvement) from baseline in PASI score.
Time frame: Baseline and Weeks 8, 16, and 24
Percentage of Participants Who Achieved a PASI 100 Response Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is defined as a 100% reduction (improvement) from baseline in PASI score.
Time frame: Baseline and Weeks 8, 16, and 24
Change From Baseline in PASI Score Over Time
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
Time frame: Baseline and weeks 8, 16, and 24
Percent Change From Baseline in PASI Score
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
Time frame: Baseline and weeks 8, 16, and 24
Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of Cleared or Minimal Over Time
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
Time frame: Weeks 8, 16, and 24
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.
Time frame: Baseline and weeks 8, 16, and 24
Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.
Time frame: Baseline and weeks 8, 16, and 24
Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.
Time frame: Baseline, weeks 8, 16, and 24
Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.
Time frame: Baseline, weeks 8, 16, and 24
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Over Time
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.
Time frame: Baseline and Weeks 8, 16, and 24
Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24
Time frame: Baseline and week 24
This single-arm, open-label longitudinal study was conducted at 12 sites in Canada from 5 August 2014 to 17 March 2017. The study entailed a screening period up to 35 days, a 24-week treatment period, and a 70-day safety follow-up period. Participants continued to receive adalimumab (ADA) and had oral methotrexate (MTX) added to their treatment.
| Milestone | Adalimumab + Methotrexate |
|---|---|
| Started | 46 |
| Completed | 43 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Non-adherence to protocol | 1 |
Study investigators were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment | 33.3 (0.0 to 71.1) | 52.5 (37.0 to 68.0) | 50.0 (35.6 to 64.4) |
Participants were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment | 16.7 (0.0 to 46.5) | 52.5 (37.0 to 68.0) | 47.8 (33.4 to 62.3) |
Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Baseline | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
| Week 8 | 50.0 (10.0 to 90.0) | 42.5 (27.2 to 57.8) | 43.5 (29.2 to 57.8) |
| Week 24 | 33.3 (0.0 to 71.1) | 60.0 (44.8 to 75.2) | 56.5 (42.2 to 70.8) |
Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Baseline | 0 (0.0 to 0.0) | 17.5 (5.7 to 29.3) | 15.2 (4.8 to 25.6) |
| Week 8 | 16.7 (0.0 to 46.5) | 52.5 (37.0 to 68.0) | 47.8 (33.4 to 62.3) |
| Week 24 | 16.7 (0.0 to 46.5) | 60.0 (44.8 to 75.2) | 54.3 (40.0 to 68.7) |
Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied
| Participants | Adalimumab + Methotrexate |
|---|---|
| Baseline — Completely satisfied | 0 |
| Baseline — Highly satisfied | 0 |
| Baseline — Slightly satisfied | 8 |
| Baseline — Moderately dissatisfied | 31 |
| Baseline — Completely dissatisfied | 7 |
| Baseline — Missing | 0 |
| Week 8 — Completely satisfied | 6 |
| Week 8 — Highly satisfied | 14 |
| Week 8 — Slightly satisfied | 15 |
| Week 8 — Moderately dissatisfied | 9 |
| Week 8 — Completely dissatisfied | 1 |
| Week 8 — Missing | 1 |
| Week 16 — Completely satisfied | 8 |
| Week 16 — Highly satisfied | 15 |
| Week 16 — Slightly satisfied | 10 |
| Week 16 — Moderately dissatisfied | 8 |
| Week 16 — Completely dissatisfied | 3 |
| Week 16 — Missing | 2 |
| Week 24 — Completely satisfied | 11 |
| Week 24 — Highly satisfied | 15 |
| Week 24 — Slightly satisfied | 7 |
| Week 24 — Moderately dissatisfied | 6 |
| Week 24 — Completely dissatisfied | 4 |
| Week 24 — Missing | 3 |
Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied
| Participants | Adalimumab + Methotrexate |
|---|---|
| Baseline — Completely satisfied | 5 |
| Baseline — Highly satisfied | 2 |
| Baseline — Slightly satisfied | 15 |
| Baseline — Moderately dissatisfied | 17 |
| Baseline — Completely dissatisfied | 7 |
| Baseline — Missing | 0 |
| Week 8 — Completely satisfied | 10 |
| Week 8 — Highly satisfied | 12 |
| Week 8 — Slightly satisfied | 14 |
| Week 8 — Moderately dissatisfied | 7 |
| Week 8 — Completely dissatisfied | 2 |
| Week 8 — Missing | 1 |
| Week 16 — Completely satisfied | 7 |
| Week 16 — Highly satisfied | 15 |
| Week 16 — Slightly satisfied | 13 |
| Week 16 — Moderately dissatisfied | 6 |
| Week 16 — Completely dissatisfied | 3 |
| Week 16 — Missing | 2 |
| Week 24 — Completely satisfied | 10 |
| Week 24 — Highly satisfied | 15 |
| Week 24 — Slightly satisfied | 7 |
| Week 24 — Moderately dissatisfied | 6 |
| Week 24 — Completely dissatisfied | 5 |
| Week 24 — Missing | 3 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is defined as at least a 50% reduction (improvement) from baseline in PASI score.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 50.0 (10.0 to 90.0) | 42.5 (27.2 to 57.8) | 43.5 (29.2 to 57.8) |
| Week 16 | 50.0 (10.0 to 90.0) | 62.5 (47.5 to 77.5) | 60.9 (46.8 to 75.0) |
| Week 24 | 66.7 (28.9 to 100.0) | 65.0 (50.2 to 79.8) | 65.2 (51.5 to 79.0) |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from baseline in PASI score.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 33.3 (0.0 to 71.1) | 27.5 (13.7 to 41.3) | 28.3 (15.2 to 41.3) |
| Week 16 | 16.7 (0.0 to 46.5) | 42.5 (27.2 to 57.8) | 39.1 (25.0 to 53.2) |
| Week 24 | 16.7 (0.0 to 46.5) | 42.5 (27.2 to 57.8) | 39.1 (25.0 to 53.2) |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is defined as at least a 90% reduction (improvement) from baseline in PASI score.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 16.7 (0.0 to 46.5) | 12.5 (2.3 to 22.7) | 13.0 (3.3 to 22.8) |
| Week 16 | 16.7 (0.0 to 46.5) | 15.0 (3.9 to 26.1) | 15.2 (4.8 to 25.6) |
| Week 24 | 16.7 (0.0 to 46.5) | 30.0 (15.8 to 44.2) | 28.3 (15.2 to 41.3) |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is defined as a 100% reduction (improvement) from baseline in PASI score.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 16.7 (0.0 to 46.5) | 12.5 (2.3 to 22.7) | 13.0 (3.3 to 22.8) |
| Week 16 | 16.7 (0.0 to 46.5) | 10.0 (0.7 to 19.3) | 10.9 (1.9 to 19.9) |
| Week 24 | 16.7 (0.0 to 46.5) | 27.5 (13.7 to 41.3) | 26.1 (13.4 to 38.8) |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
| units on a scale | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -4.6 ± 2.07 | -4.6 ± 0.65 | -4.6 ± 0.61 |
| Week 16 | -4.5 ± 1.31 | -6.2 ± 0.59 | -5.9 ± 0.53 |
| Week 24 | -3.1 ± 3.17 | -6.3 ± 0.68 | -5.9 ± 0.74 |
PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).
| percent change | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -51.6 ± 16.23 | -43.7 ± 6.11 | -44.8 ± 5.64 |
| Week 16 | -45.6 ± 15.15 | -59.2 ± 5.06 | -57.3 ± 4.74 |
| Week 24 | -17.4 ± 45.65 | -63.7 ± 5.78 | -58.1 ± 8.01 |
The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 16.7 (0.0 to 46.5) | 27.5 (13.7 to 41.3) | 26.1 (13.4 to 38.8) |
| Week 16 | 16.7 (0.0 to 46.5) | 35.0 (20.2 to 49.8) | 32.6 (19.1 to 46.2) |
| Week 24 | 16.7 (0.0 to 46.5) | 47.5 (32.0 to 63.0) | 43.5 (29.2 to 57.8) |
The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.
| percentage of body surface area | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -3.5 ± 2.95 | -4.5 ± 1.06 | -4.4 ± 0.98 |
| Week 16 | -4.5 ± 2.40 | -6.4 ± 1.08 | -6.2 ± 0.99 |
| Week 24 | -4.1 ± 1.57 | -6.3 ± 0.89 | -6.0 ± 0.79 |
The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.
| percent change | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -33.9 ± 23.10 | -34.1 ± 7.48 | -33.4 ± 7.17 |
| Week 16 | -34.1 ± 22.25 | -54.2 ± 5.89 | -51.4 ± 5.89 |
| Week 24 | -32.7 ± 22.25 | -61.7 ± 6.33 | -57.8 ± 6.21 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.
| units on a scale | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -5.0 ± 1.40 | -4.8 ± 0.71 | -4.8 ± 0.64 |
| Week 16 | -3.8 ± 2.54 | -5.9 ± 0.78 | -5.6 ± 0.76 |
| Week 24 | -1.7 ± 4.29 | -6.3 ± 0.69 | -5.4 ± 0.88 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.
| percent change | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | -43.0 ± 21.50 | -38.6 ± 7.01 | -39.2 ± 6.48 |
| Week 16 | -22.9 ± 40.40 | -38.9 ± 12.79 | -36.7 ± 11.85 |
| Week 24 | 14.4 ± 71.98 | -55.0 ± 6.90 | -44.5 ± 11.11 |
The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.
| percentage of participants | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Week 8 | 16.7 (0.0 to 46.5) | 20.0 (7.6 to 32.4) | 19.6 (8.1 to 31.0) |
| Week 16 | 16.7 (0.0 to 46.5) | 40.0 (24.8 to 55.2) | 37.0 (23.0 to 50.9) |
| Week 24 | 16.7 (0.0 to 46.5) | 40.0 (24.8 to 55.2) | 37.0 (23.0 to 50.9) |
| mg/L | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Adalimumab + Methotrexate |
|---|---|---|---|
| Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24 | -2.6 ± 0.47 | 0.1 ± 1.52 | -0.3 ± 1.32 |
Collected over From the date of either the first dose of study adalimumab or the first dose of methotrexate up to 70 days after the last adalimumab injection during the study. The median duration of exposure to adalimumab was 168 days (range: 14 - 171 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab + Methotrexate | 0/46 (0%) | 1/46 (2.2%) | 27/46 (58.7%) |
| Event | Adalimumab + Methotrexate |
|---|---|
| Cardiac arrestCardiac disorders | 1/46 |
| Generalised tonic-clonic seizureNervous system disorders | 1/46 |
| Loss of consciousnessNervous system disorders | 1/46 |
| HypercapniaRespiratory, thoracic and mediastinal disorders | 1/46 |
| Event | Adalimumab + Methotrexate |
|---|---|
| NasopharyngitisInfections and infestations | 7/46 |
| Upper respiratory tract infectionInfections and infestations | 5/46 |
| NauseaGastrointestinal disorders | 3/46 |
| BronchitisInfections and infestations | 3/46 |
| FatigueGeneral disorders | 2/46 |
| GastroenteritisInfections and infestations | 2/46 |
| PneumoniaInfections and infestations | 2/46 |
| SinusitisInfections and infestations | 2/46 |
| Tooth abscessInfections and infestations | 2/46 |
| Urinary tract infectionInfections and infestations | 2/46 |
| Age, Continuous(years) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| Mean | 41.0 ± 13.84 | 47.3 ± 11.91 | 46.5 ± 12.20 |
| Age, Customized(Participants) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| < 40 years | 2 | 13 | 15 |
| 40 - 64 years | 4 | 22 | 26 |
| ≥ 65 years | 0 | 5 | 5 |
| Sex: Female, Male(Participants) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| Female | 2 | 9 | 11 |
| Male | 4 | 31 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 39 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| White | 4 | 31 | 35 |
| Black | 0 | 1 | 1 |
| Asian | 2 | 8 | 10 |
| Duration of Psoriasis(years) | Primary Sub-optimal Responders - ADA + MTX | Secondary Sub-optimal Responders - ADA + MTX | Total |
|---|---|---|---|
| Mean | 20.623 ± 10.4819 | 21.760 ± 9.7403 | 21.612 ± 9.7253 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2014 to primary completion in Mar 2017, 31 months.
Results were first posted in Mar 2018, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Methotrexate